It goes one step further as a triple-agonist, targeting GLP-1, GIP, and glucagon receptors, which may enhance fat metabolism
A recent meta-analysis found no link between GLP-1 agonists and pancreatitis in people with Type 2 diabetes, but some case reports challenge this
But the states new Action Plan for Healthy Eating and Active Living, written by a coalition of groups in South Carolina, including the Department of Public Health, makes no mention of GLP-1s or the role they might play in lowering obesity rates in the state
The medication itself is FDA-approved, just not for that particular purpose
Avoid using mini-bars for unopened pens that require 3646F storage
Emerging research suggests GLP-1 may also affect reward pathways, potentially influencing taste perception